Latest Breaking News On - Wolfgang dummer - Page 1 : vimarsana.com

Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M D , Ph D , as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)

SEATTLE (BUSINESS WIRE) Oct 4, 2023

United statesTemre johnsonWolfgang dummerAndrew sandlerTechnical university of munichClinical development at biomarinSecurities exchangeAlpine immune sciences incGlobal development leaderAlpine immune sciencesRigel pharmaceuticalsExchange commissionImmune sciencesChief medical officerExecutive chairmanChief executive

Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it dosed the first patient in its Phase 1b study of R289, an IRAK1/4 dual inhibitor,.

United statesSouth san franciscoDavid rosenWolfgang dummerExchange commissionRigel pharmaceuticals incPrnewswire rigel pharmaceuticals incPyroptosis driveQuarterly reportRigel pharmaceuticals

Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSouth san franciscoWolfgang dummerExchange commissionRigel pharmaceuticals incPrnewswire rigel pharmaceuticals incRigelrigel pharmaceuticals incRigelrigel pharmaceuticalsPyroptosis driveLooking statements thisQuarterly reportRigel pharmaceuticalsDavid rosenargot partners

Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the publication of data in The Lancet Haematology, which summarizes the Phase 1.

United statesSouth san franciscoDavid rosenWolfgang dummerRigel pharmaceuticals incLeukemia lymphoma societyForma therapeutics incDrug administrationExchange commissionEuropean medicines agencyAmerican cancer societyRigel pharmaceuticalsLancet haematologyForma therapeuticsNew orleansNew drug application

Rigel Pharmaceuticals, Inc (RIGL) CEO Raul Rodriguez on Q2 2022 Results - Earnings Call Transcript

Rigel Pharmaceuticals, Inc. (NASDAQ:NASDAQ:RIGL) Q2 2022 Earnings Conference Call August 02, 2022, 04:30 PM ET Company Participants Dolly Vance - Executive Vice President, Corporate Affairs.

United statesKalpit patelKristen kluskaWolfgang dummerRaul rodriguezGary nachmanEli lillyDave santosEun yangJoe pantginisJorge cortesDolly vanceYigal nochomovitzCompany participantsUs department of defenseRigel pharmaceuticals inc